等待开盘 02-10 09:30:00 美东时间
+0.250
+3.57%
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
01-07 02:42
Citizens Capital Markets analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:ACET) from Market Perform to Market Perform.
2025-03-07 23:08
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-12 00:13
Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $19 to $8.
2024-09-11 23:25
HC Wainwright & Co. analyst Edward White downgrades Adicet Bio (NASDAQ:ACET) from Buy to Neutral.
2024-09-11 18:18